TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06483048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MUC1-activated T-cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and possible ascites sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05093959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: An extended release formulation will be used which improves compliance and reduces GI side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
Study: NCT06276777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth varnish (PRG Barrier Coat from Shofu)
Description: Treatment of cervical dentin hypersensitivity with tooth desensitizers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth varnish (Clinpro white varnish 3M)
Description: Treatment of cervical dentin hypersensitivity with tooth desensitizers.
Study: NCT06018025

Intervention type: DRUG
Intervention: CGRP antibody
Description: treatment with CGRP antibody for 4 months

Intervention type: DRUG
Intervention: CGRP antibody
Description: treatment with CGRP antibody for 4 months
Study: NCT06053892

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Puncture
Description: Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Puncture
Description: Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Puncture
Description: Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.
Study: NCT05887167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cells added to planned CAR T
Description: Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
Study: NCT06330792

Intervention type: OTHER
Group type: OTHER
Intervention: bio-mechanical awareness
Description: Biomechanical awareness advices for physiotherapists during session: consist of group of awareness advices and McKenzie extension part method exercises to help physiotherapist working in correct position and consume his energy.

Intervention type: OTHER
Group type: OTHER
Intervention: core stability exercises
Description: Core stabilization exercise Program: The procedure for core stabilization exercises to improve core muscles in lumbar area

Intervention type: OTHER
Group type: OTHER
Intervention: core stability exercises
Description: Core stabilization exercise Program: The procedure for core stabilization exercises to improve core muscles in lumbar area
Study: NCT04779580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic
Description: Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcostal Nerve Block Using Local Anaesthetic
Description: Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
Study: NCT05730244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cassia alata extract
Description: 1 ml Cassia alata extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml placebo solution
Study: NCT05836740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline hydrochloride capsule
Description: 50 mg per capsule, containing 50mg of Minocycline Hydrochloride.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules of Minocycline hydrochloride capsules
Description: 50 mg per capsule, containing 0mg of Minocycline Hydrochloride.
Study: NCT05715489

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of pre and postoperative POP-Q values of the patients
Description: Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of pre and postoperative PISQ-12 scores of the patients
Description: Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
Study: NCT06452849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nervio-X
Description: An 8-channel TIS device developed by NEURODOME Corporation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nervio-X
Description: An 8-channel TIS device developed by NEURODOME Corporation.
Study: NCT05092243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study: NCT06381011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Vibration
Description: The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Local Vibration
Description: The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
Study: NCT05017324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WGS DST strategy
Description: WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
Study: NCT05800782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face Memory Training
Description: Computer-based training using faces targeting face memory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face Perception Training
Description: Computer-based training using faces targeting improving face perception

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control training
Description: Computer-based training using faces not targeting improving face perception or memory
Study: NCT05142982

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
Study: NCT06026722

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive behavioral therapy for insomnia
Description: CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for insomnia
Description: CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
Study: NCT05799664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLD
Description: Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TLD procedure
Description: Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care
Description: Patients will also receive standard of care that meet the recommendations of GOLD guideline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients will also receive standard of care that meet the recommendations of GOLD guideline.
Study: NCT05157841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension 266 mg
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension 266 mg
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Sciatic nerve block in the popliteal fossa with Bupivacaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Sciatic nerve block in the popliteal fossa with Bupivacaine HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension 133 mg
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension 133 mg
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
Study: NCT04662528

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 1g capsules/day
Study: NCT01122004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study: NCT04662528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT9001 (omega-3 pentaenoic acid)
Description: 4 x 1g capsules/day
Study: NCT05385952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GATT-Patch
Description: GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver.
Study: NCT05196048

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05385952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil
Description: TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.
Study: NCT05369208

Intervention type: DRUG
Group type: OTHER
Intervention: Avatrombopag Oral Tablet
Description: Avatrombopag 20 mg given once daily (initial dose). Dose adjustments will be determined by the physician and in accordance with the overseas Doptelet prescribing information.
Study: NCT05622071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
Study: NCT06550011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-110 Low Dose
Description: Low dose. lower than the safety factor of 10 as recommended by the FDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-110 Medium Dose
Description: Medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-110 High Dose
Description: High Dose
Study: NCT04760730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers
Study: NCT06354335

Intervention type: OTHER
Intervention: Employees exposed to a major hospital reorganisation
Description: Occupational exposure
Study: NCT04949139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: Reducing the sodium concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: Reducing the sodium concentration
Study: NCT05032118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Titratable ketamine infusion + low fixed-dose propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Standard of care titratable propofol infusion.
Study: NCT06323811

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMR
Description: Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMR
Description: Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CMR
Description: Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMR
Description: Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMR
Description: Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Study: NCT05425030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Sodium Salt Substitute
Description: Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information/Education
Description: Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information/Education
Description: Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
Study: NCT05675527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose PRP
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose PRP
Description: Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection
Study: NCT05743101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin simulant
Description: Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
Study: NCT04855292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 injection
Description: TG103 injection, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 injection
Description: TG103 injection, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 injection
Description: TG103 injection, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control, SC, once weekly
Study: NCT05605496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137
Description: IV infusion, 14mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137
Description: IV infusion, 14mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137
Description: IV infusion, 14mg/kg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1/PD-L1
Description: IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1/PD-L1
Description: IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1/PD-L1
Description: IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
Study: NCT06342622

Intervention type: DIAGNOSTIC_TEST
Intervention: Using routine clinical data and machine learning models.
Description: This study used clinical data and machine learning model to screen young-onset colorectal cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Using routine clinical data and machine learning models.
Description: This study used clinical data and machine learning model to screen young-onset colorectal cancer.
Study: NCT05667974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried
Description: PIKA rabies vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chirorab
Description: Active Comparator